# Ligand Pharmaceuticals

Ligand Pharmaceuticals is an Asset Manager based in San Diego, United States.

## Overview

- **Organization type:** Asset Manager
- **Headquarters:** San Diego, United States
- **Region:** North America
- **Address:** San Diego, CA, United States
- **Founded:** 1987
- **Assets under management:** Undisclosed
- **Website:** ligand.com
- **LinkedIn:** https://www.linkedin.com/company/ligand-pharmaceuticals

## Regulatory record

- **Reports private funds:** No

## About

Ligand Pharmaceuticals develops and acquires technologies for pharmaceutical companies to discover and develop medicines. It manages a portfolio of biopharmaceutical royalties and utilizes its Captisol technology platform in drug development. The company was founded in 1987 and is based in San Diego, California.

## Sectors

- Biotech
- Pharmaceuticals

## People

- John L. Higgins — CEO
- Matthew W. Foehr — Chairman

## Questions

### How does Ligand Pharmaceuticals generate revenue?

Ligand generates revenue primarily through royalty payments on approved drugs and milestone payments from licensing agreements. It does not manufacture or market drugs itself. The model involves acquiring or co-funding late-stage compounds and then collecting a percentage of future sales (per public financial filings).

### Does Ligand Pharmaceuticals manage external capital?

No, Ligand is a publicly traded company (NASDAQ: LGND) that manages its own balance sheet. It does not raise pooled investor capital like a traditional asset manager or family office. Its funding comes from its own cash flow and debt financing (per SEC filings).

### Which sectors does Ligand Pharmaceuticals focus on?

Ligand's portfolio concentrates on biotech and pharmaceuticals, specifically oncology, central nervous system disorders, and infectious diseases. It avoids non-healthcare sectors. The firm also has an animal health division, allowing it to diversify within healthcare (per annual reports).

### How does Ligand Pharmaceuticals manage risk in its portfolio?

Ligand mitigates risk by diversifying across dozens of partnered programs and multiple therapeutic areas. It avoids drug-development failure risk by focusing on approved or late-stage assets. Additionally, its contracts include milestone payments that create cash flow before final approval (per investor relations materials).

## Related profiles

- [Wesray Social Investments LLC](https://altss.com/profile/wesray-social-investments-llc)
- [RudderStack](https://altss.com/profile/rudderstack)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/ligand-pharmaceuticals

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology